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Abstract : The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) is still poor, and the 5-year sur-
vival rate in patients undergoing radical surgery (R0) is less than one-third. Since the prognosis depends main-
ly on tumor factors, so early diagnosis is necessary. To extend the survival time of these patients with a poor 
prognosis, cases of long-term survival were examined based on the results of our experiences and the literature. 
It was found that the hepatitis virus was highly involved in the carcinogenesis of ICC, and patients who were 
infected with hepatitis virus had rather good survival. J. Med. Invest. 68 : 15-21, February, 2021
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INTRODUCTION
 
The prognosis of patients with intrahepatic cholangiocarcino-
ma (ICC) is less than one-third of patients undergoing curative 
resection (R0) surviving for more than 5 years. The prognosis de-
pends on a high recurrence rate. So it is important to find more 
effective adjuvant therapy to prevent this recurrence. The aim of 
this review article is to develop a strategy to prolong the survival 
of these difficult groups of ICC patients. 
THE HEPATITIS VIRUS IN ICC ; ROLE OF THE HEP-
ATITIS VIRUS 
In the primary liver cancers, ICC developing from the bile 
duct epithelium was relatively rare, accounting for only 21 (7.2%) 
of the 292 cases of liver cancers in the 18 years (1980-98) at 
Kumamoto University Hospital (1). It was said that ICC and 
hepatitis virus were not related, but according to Shen et al. 
(2), 198 of 429 cases (46.4%) were positive for HBsAg, and the 
number of cases has been increasing in recent reports. Epide-
miological studies in Japan and Asia have shown that chronic 
hepatitis, such as hepatitis B and hepatitis C, and progression 
to liver cirrhosis are also important factors in the development 
of ICC, and the reasons for this were shown by the RIKEN 
team. These studies were performed by a joint research group 
(including 37 other collaborators) with Hidetoshi Nakagawa as 
the leader and Akihiro Fujimoto as the vice leader of the Genome 
Research Team of the RIKEN Center for Biomedical Sciences 
(3, 4). To summarize these results, the collaborative research 
group used a next-generation sequencer and a supercomputer to 
decipher and identify all genomic mutations occurring in ICC. 
Next, they compared the genome mutations of 60 hepatocellular 
carcinoma (HCC) identified by the same genome-wide sequence 
analysis and found an average of 4,300 mutations per tumor on 
the whole genome of ICC. The base substitution pattern of these 
mutations was similar to that of HCC. They also discovered that 
the genome sequence of hepatitis B virus has been inserted into 
the genomes of multiple ICCs, indicating a strong involvement 
in cancer. Furthermore, it was also found that several mutated 
genes in ICC were consistent with genes that mutated frequently 
in HCC. On the other hand, mutations in genes specifically found 
in cholangiocarcinoma outside the liver (extrahepatic cholangio-
carcinoma) were also found in ICC. These cases have proven to 
have a very poor prognosis.
SURGICAL PROCEDURE FOR R0 RESECTION
 
First and second authors’ experiences from 1980 to 1998 at Kumamoto 
University Hospital.
In the beginning, full resection was the only means to cure 
ICC, and we applied the concepts, technologies of vascular 
surgery, and hepatic transplant surgery, so worked on how 
to perform surgery aimed at R0 resection. In three cases, we 
performed surgery aiming at R0 applying these techniques for 
advanced ICC patients. The three cases that underwent these 
operations are presented below. 
Case 1 : A 51-year-old woman
The patient was admitted to our clinic on May 24, 1990, with 
jaundice as the chief complaint. Computed tomography (CT) 
showed a low-density mass (6 cm in diameter) with an irregular 
shape in segments IV and V and two small, low-density masses 
in segments VI and VIII.
Superior mesenteric arteriography showed encasement of the 
right hepatic artery, which branched off the superior mesenteric 
artery of approximately 5 cm in length. The left hepatic artery 
branched off from the left gastric artery, and the medial branch 
of the left hepatic artery was connected with the right anterior 
branch, making collateral vessels due to stenosis of the right 
anterior hepatic artery. On transarterial portal vein imaging, 
smooth encasement was shown approximately 2 cm in length on 
the trunk of the portal vein. On the basis of these imaging stud-
ies, ICC with lymph node involvement in the hepatoduodenal 
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ligament was diagnosed. Therefore, liver resection of the right 
3 segments with hepatoduodenal ligamentectomy (combined en 
bloc resection of the extrahepatic bile duct, the hepatic artery, 
the portal vein, and lymph node dissection in the hepatoduode-
nal ligament) and lymph node dissection around the abdominal 
aorta were carried out. The histological summary according to 
the Japanese Classification of Primary Liver Cancer was as fol-
lows : mass forming type + periductal type, moderately differen-
tiated tubular adenocarcinoma, Mt (4)-A(2), 5.6 × 3.9 cm2, 3 × 3 
cm2, P (1) 3 × 3 cm2, L (1) 1 × 1 cm2, Hg, Fc (-), S1, N2, Vp0, Vv0, 
B1(RHD), PV2 (by metastatic lymph node), A2 (by metastatic 
lymph node), IM3, P0, Z0, EV(-). NL : n3 (No 3 1 / 6, 12p 1 / 1, 13a 
2 / 5, 14 1 / 1, 16 (para-aortic lymph node) 4 / 11), pv2, a1, T4, N1, 
M1, stage 1VB, Hr 3 (PAML) + Hr0 (L), + D2+α (para-aortic 
lymph node dissection), SM (-), and Curability B (with no cancer 
at the surgical margin).
She survived 5 years and 10 months after surgery, but died 
on April 1, 1996. The cause of death was multiple metastases 
to the liver and lumbar and pelvic bones. It was thought that 
this patient should have been given adequate postoperative 
chemotherapy.
Fortunately, in this case, the right hepatic artery branched 
from the superior mesenteric artery, and the left hepatic artery 
branched from the left gastric artery ; therefore, the circulation 
of the remaining liver in the left lateral segment was main-
tained, and there was thus no need to remove or reconstruct the 
left hepatic artery. It could be resected en bloc, including the bil-
iary tract, the portal vein, right hepatic artery, and lymph nodes 
in the hepatoduodenal ligament, and each vessel could be easily 
rebuilt. Thus, surgery could be performed without cancer at the 
stump. However, this patient experienced recurrence and died 
5 years and 10 months after the surgery, suggesting the need 
for postoperative adjuvant chemotherapy. The regimen and the 
administration period, etc., require further study.
Case 2. A 54-year-old man
The patient had experienced dull abdominal pain in the epi-
gastrium since May 1992. A large tumor in the liver was seen on 
ultrasonography (US) ordered by his primary care doctor. The 
patient was referred and admitted to our clinic on July 3, 1992. 
US showed a large, low echoic mass (10 × 8 cm) in segments I and 
IV and obstruction of the middle hepatic vein. In addition, two 
small low-echoic masses (2.1 cm and 1.2 cm in diameter) were 
observed in segments V and VIII. Dynamic CT demonstrated a 
large mass in segments I ~ IV, and the inferior vena cava (IVC) 
was not detected in the hepatic portion. The tumor was 9 cm in 
diameter and had low intensity on T1-weighted imaging with a 
stricture at the origin of the right hepatic vein, and high inten-
sity on T2-weighted imaging of magnetic resonance imaging 
(MRI). Arteriography of the common hepatic artery showed a 
large tumor with light staining in segment IV, with a few small 
light tumor stains surrounding the main tumor. The IVC was 
occluded on IVC venography, and the IVC blood flow was flowing 
to the intrahepatic vein with collateral veins through the right 
inferior hepatic vein, and it was drained from the right hepatic 
vein to the suprahepatic IVC. Based on the preoperative imaging 
diagnosis, an infiltrative obstruction in the hepatic portion of the 
IVC due to a large ICC from S I to S IV was diagnosed, but there 
were no clear extrahepatic lymph node metastases. Venography 
of the IVC showed obstruction of the hepatic IVC and many col-
lateral veins in the liver through the right inferior hepatic vein. 
It is impossible to perform removal of liver cancer invading the 
IVC without total hepatic vein exclusion (THVE) (5-7). Although 
THVE is a simple exclusion, it has an acceptable range of only 40 
to 60 minutes. Therefore, it was decided to perform liver resec-
tion and IVC resection and reconstruction under hepatic cooling 
reperfusion. Left and caudal lobectomy with resection of the IVC 
by in situ hypothermic-perfused liver surgery was carried out. 
First, in situ hypothermic-perfused liver surgery was started 
using the veno-venous bypass technique under total hepatic 
vascular exclusion. After IVC resection, an approximately 10-cm 
defect of the IVC was reconstructed with a 20-mm expanded 
EPTFE graft (ringed Gore-Tex) (5). Veno-venous time and total 
hepatic exclusion time were 187 and 181 minutes, respectively. 
Bypass flow was 1.3 - 2.1 L / min. Next, the two daughter tumors 
in segment V were extirpated. 
The macroscopic findings were as follows : T4, N0, M0, Stage 
1V, Curability 3, P3, Vv3. In the cut face of the resected speci-
men, the IVC was surrounded and compressed by the S IV and 
S I tumors, and it was closed. The histology of the tumor was 
moderately differentiated adenocarcinoma. The patient had a 
good quality of life postoperatively. After postoperative adjuvant 
therapy with 5-fluorouracil (5-Fu) 250 mg / day + cis-diamine 
dichloroplatinum (CDDP) 125 mg for 2 weeks, he was discharged 
7 weeks after surgery. However, he died of lung and liver metas-
tases 10 months after surgery.
Hepatic resection under liver cooling reperfusion was per-
formed in 3 cases including this case, and the postoperative 
course was good in all cases. THVE with a hepatic temperature 
of 23 - 25°C for 3 hours was temporary and transient to avoid 
postoperative liver injury, since it has been found that THVE 
under cooling reperfusion is possible for 3 hours.
Case 3 : A 59-year-old man 
The patient was admitted to our clinic with general fatigue 
and epigastric pain as chief complaints. He had no jaundice, ane-
mia, or swollen superficial lymph nodes. The liver was palpable 
10 cm below the xiphoid process, with an elastic hard consisten-
cy, rounded edge, and uneven surface. 
The spleen was not palpable, and ascites and edema were 
absent. Blood chemistry showed slightly elevated transaminase 
levels, and there were no abnormal coagulation findings. The 
indocyanine green (ICG) test was within normal limits. Hepatic 
US showed a large mass without a halo in segments II, III, IV, 
V, and VI of the liver. This mass clearly compressed the right 
hepatic vein and IVC. CT also demonstrated a large low-density 
mass, measuring 13 × 9 cm2 at the same site in the liver, which 
was observed to have compressed the right hepatic vein and IVC. 
Venography of the IVC showed compression, approximately 10 
cm in length from the ventral side, by the tumor with collateral 
vessels. Based on the above imaging examination, the tumor was 
diagnosed as a large ICC, and infiltration of the IVC and right 
hepatic vein by the large tumor, located from the left hepatic lobe 
to the anterior of the right lobe, was suspected, which rendered 
the situation unresectable by conventional techniques. Then, 
two joint conferences with the Department of Anesthesiology, 
Central Surgery staff, Intensive Care Unit Department, and 
surgery staff were convened before the operation. After thor-
ough discussion, it was decided to perform extracorporeal liver 
resection on the ex situ perfused liver (8). Ex vivo left trisegmen-
tectomy with partial resection of the right hepatic vein by bench 
surgery after removing the whole liver was carried out. The 
summary of the surgery is as follows : the surgical procedure 
was extracorporeal surgery with left hepatic trisegmentectomy, 
lymphatic dissection, and partial resection of the right hepatic 
vein. An autologous transplant of the right posterior segment 
was then performed. Veno-venous bypass time was 5 hours and 
30 minutes, and bench operation time was 4 hours and 9 min-
utes. The duration of the anhepatic phase was 5 hours and 20 
minutes. The bleeding volume was 6,500 ml, and transfusion 
volume was 5,000 ml. The operation time was 15 hours and 45 
minutes. After extracorporeal hepatectomy, AST was 578 U / l, 
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and ALT was 480 U / l on the 2nd day, and they then gradually 
decreased. On the 9th day, AST and ALT were 46 U / l and 64 
U / l, respectively, and they then continued in double digits. How-
ever, total bilirubin increased to 13.0 mg / dl on the next day and 
decreased to 8.7 mg / dl on the third day, but it then increased for 
a while and reached 16 mg / dl on the 9th day after the operation. 
Therefore, bilirubin adsorption and plasma exchange therapy 
were started and continued, but the level did not improve. To 
identify the cause of cholestasis, blood flow of the portal vein and 
hepatic vein was confirmed by ultrasound Doppler examination, 
and on hepatic arteriography, the hepatic artery and portal vein 
were well imaged without any obstruction. Bleeding from gastric 
ulcers occurred from the 78th day after the operation, and liver 
function further deteriorated. Renal failure also developed, and 
he died of liver failure 3.5 months after surgery. Three factors 
were considered as the causes of liver failure : (1) hepatic resec-
tion was too large, with 75% massive resection of the liver (re-
sidual liver ; 25%) ; (2) damage to the peripheral small bile duct 
epithelium due to prolonged low temperature ; and (3) since there 
was an intraperitoneal infection due to bile leakage from the cut 
surface of the liver, postoperative liver regeneration was delayed. 
It was thought that, due to the overlap of these causes, recovery 
of sufficient liver function could not be achieved.
In their first paper on extracorporeal hepatectomy, Pichlmayr 
et al. (8) stated that “postoperative cholestasis could have sig-
nificant hazard in the postoperative course after an ex situ 
procedure.” At autopsy, the weight of the remaining liver was 
1,180 g, which was twice as large as that at the time of surgery, 
and it was a jaundiced liver. However, dilatation of the intra-
hepatic bile duct was not observed. There was no intrahepatic 
metastatic lesion or recurrence. The anastomoses of the portal 
vein, hepatic artery, and inferior vena cava were also opened. 
Pichlmayr et al. (8) performed the world’s first extracorporeal 
liver resection on the ex situ perfused liver for malignant tumors 
in the liver on February 1988, and 10 cases were performed by 
March 1990. The first 10 cases were performed by Pichlmayr 
et al., and four (45%) of them developed liver failure ; one died 
at 44 days, and three cases died of liver failure even after liver 
retransplantation. These four patients underwent a greater than 
65% massive hepatectomy. The eleventh case succeeded in resec-
tion of S IV and S VIII for metastatic liver cancer by Sugimachi 
et al. on March 22, 1990 (9). The twelfth case was our case and 
was performed on June 22, 1990 (10). In our case, 75% massive 
hepatectomy was performed, and only 25% remained. Therefore, 
it was thought that the surgical indication for extracorporeal 
liver resection should be stricter than for conventional liver re-
section. Currently, adjuvant therapy such as anti-PD-1 antibody 
and lenvatinib should be performed before and / or after surgery 
(details described below). Also recently, as adjuvant therapy, LIU 
Xiaoliang et al. (11) performed programmed cell death protein1 
(PD-1) blockade therapy and / or radiotherapy for three patients 
with high tumor mutation burden (TMB), high microsatellite 
instability (MSI-H), deficient mismatch repair (dMMR), and / or 
positive programmed cell death ligand 1 (PD-L1) expression. 
They provided the first report on the therapeutic responses of 
ICC patients treated with combined PD-1 blockade with stereo-
tactic body radiotherapy (SBRT) (cyberknife) in the background 
of low TMB, MSS, pMMR, and negative PD-L1 expression. 
One stage 4A ICC patient and two postsurgical recurrent ICC 
patients were involved in this study, and the responses to the 
combined therapy of both locally irradiated tumor(s) and the 
abscopal tumors or metastases were assessed by magnetic res-
onance imaging (MRI) and positron emission tomography-com-
puted tomography (PET-CT). The stage IVA ICC patient (patient 
A) had a TMB of 1.2 muts / Mb with MSS, pMMR, and PD-L1 
expression < 1%. Both the intrahepatic lesion and the lymph 
node metastases were well controlled for 7 months, and partial 
response (PR) was achieved, with the sum of lesion diameters de-
creased by 40.9%. Postsurgical recurrent ICC patients (Patient 
B) had a TMB of 3.8 muts / Mb with MSS, pMMR, and PD-L1 
expression < 1%. Both the recurrent intrahepatic lesion and the 
lymph node metastases were well controlled by the combined 
therapy, and the sum of lesion diameter decreased by 86.3% 
(PR). The other postsurgical recurrent patient (Patient C) had a 
TMB of 0.98 muts / Mb with MSS, pMMR, and PD-L1 expression 
< 1%, and achieved complete response (CR) that was maintained 
for 11 months. Abscopal effects were observed in all three pa-
tients. This study provided the first evidence for the effectiveness 
of combined SBRT and PD-1 blockade therapy in late-stage or re-
current ICC patients with low TMB, MSS, pMMR, and negative 
PD-L1 expression, and potentially expanded the indications for 
the combined therapy to such patients who were previously not 
suitable for immunotherapy. Furthermore, PD-1 blockade with 
stereotactic body radiotherapy (SBRT) seems to be appropriate 
for cases where surgery is not possible due to reduced immunity. 
The progress of another case of anti-PD inhibitor treatment (12) 
that achieved a good response will be detailed later. In addition, 
drugs such as geranylgeranylacetone (13) (a non-toxic HSP70 
inducer) to prevent postoperative liver failure are necessary, and 
it may be important to consider once again whether R0 surgery 
is possible with massive hepatectomy under low-temperature in 
situ perfusion of the liver in the body.
Liver resection and results of ICC patients at The University of 
Tokushima Hospital
ICC surgeries (14 males and 9 females) were performed over 
the 9 years from April 1994 to July 2002 at The University of 
Tokushima Hospital, where the first author went after Kumamoto 
University Hospital. The patients’ average age was 65 years. In 
11 cases of peripheral type and 12 cases of portal hilar type, the 
operation methods were : right, 3-segment resection, 4 cases ; left 
3-segment resection, 1 case ; extended right hepatic lobectomy, 
1 case ; extended left hepatic lobectomy, 7 cases ; right hepatic 
lobectomy, 1 case ; right anterior segmentectomy, 1 case ; right 
posterior segmentectomy, 2 cases ; and partial liver resection, 
3 cases. In total, major hepatic resection was performed for 20 
cases (87%), and resection of the extrahepatic bile duct was also 
carried out in 14 (60.1%) of these 23 cases, 8 (39.8%) were infect-
ed with the hepatitis C virus (HCV). The cumulative survival 
rates of the HCV-related ICCs are shown in Figure 1. Survival 
curves of patients who were HCV-positive were significantly 
better (p = 0.0049) than of those who were HCV-negative, but 
the reason is not clear. However, an article (14) later revealed 
the reasons. Recently, lymph node metastasis was found to be 
significantly lower in hepatitis B virus (HBV)-associated ICC 
Figure 1.　Survival curves of patients who were HCV-positive were 
significantly better (p = 0.0049) than of those who were HCV-negative.
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patients than in those without HBV infection. Seogsong et al. 
(14) found that HBV infection in cancer-associated lymphan-
giogenesis / HBV infection could be involved in the suppression 
of cancer-associated fibroblasts adopting lymphatic endothelial 
morphology and function (mesenchymal-to-lymphatic endotheli-
al transition), which resulted in the low extent of cancer-associ-
ated lymphangiogenesis and led to a relatively low incidence (14). 
They also showed decreased lymph node metastases in HBV-as-
sociated ICC. They did not discuss HCV infection, but all of our 
cases were HCV-infected, so that they had an improved survival 
rate compared with non HCV-infected cases. It was suggested 
that a similar mechanism might work to improve survival after 
resection of HCV-positive ICC. The case of a patient who sur-
vived for a long time after resection is presented. The patient was 
a 67-year-old woman who had undergone subtotal gastrectomy 
with lymph node dissection 14 years earlier. After a periodic 
follow-up visit, ALP and γGPT were increased, and US and CT 
showed dilatation of the left intrahepatic bile duct and atrophy of 
the left lateral hepatic segment. She was referred to our depart-
ment. After careful examination, she was diagnosed as having 
a small (2.5 cm in diameter), HCV-positive ICC with invasion to 
the hilar bile duct, and extended left lobectomy combined with 
resection of the caudate lobe and the extrahepatic bile duct, and 
lymphadenectomy and hepaticojejunostomy with the Roux-en-Y 
method for ICC, were performed. Lymph nodes along the lesser 
curvature of the stomach, left gastric artery, and the common 
hepatic artery had already been dissected in the operation for 
gastric cancer, so only the lymph nodes in the hepatoduodenal 
ligament with the extrahepatic bile duct were dissected in this 
procedure. She died of other disease at 8.5 years, and there was 
no recurrence at that time. Factors that contributed to long-term 
survival were : diagnosis of small tumors by periodic examina-
tion after gastric cancer surgery ; hepatitis C virus infection ; no 
lymph node metastases ; easy flow of lymph in the ICC of the 
left lobe ; and lymph nodes were dissected during gastric cancer 
surgery. Thus, it was thought that this patient survived for a 
long time without recurrence because of the overlapping of these 
four conditions.
Recent experience with combined HCC and ICC in Taoka Hospital
An 88-year-old man with left back pain visited the orthopedic 
department on March, 2019. CT showed an abnormality in the 
liver, and he was referred to our department. Blood tests showed 
increases of AFP (777.7 ng / ml), PIVKA-II (241.0 ng / ml), CEA 
(21.7 ng / ml), and CA19-9 (5.9 U / ml). Contrast-enhanced CT 
showed a tumor in the left lateral segment. The tumor was di-
agnosed as a combined tumor based on the contrast pattern and 
shape of the tumor, and this was proven by needle biopsy of the 
tumor. A left hepatic lateral segment resection was performed. 
The tumor was exposed on the serosa of the surface of the liver. 
The hepatoduodenal ligament was exposed. After taping of the 
portal vein, lymph nodes were dissected in the hepatoduodenal 
ligament. And left hepatic lateral segment resection was per-
formed. The hepatectomy specimen was a 6 x 5.5-cm2 tumor. On 
pathological examinations, it was im (-), fc-inf (-), sf (-), s (0), vp 
(2), vv(0), va (0), b (0), sm (-), 12p (-).
The patient was discharged 11 days after surgery, and 2.8 
months after surgery, multiple liver recurrences and right lung 
metastases developed, and he died 5.5 months after surgery. 
Even the combined tumor of ICC and HCC had a poor prognosis. 
Kim et al. (15) reported that patients with combined HCC and 
ICC had poor postoperative survival rates. A high CA-19-9 level 
was associated with worse survival, suggesting that the chol-
angiocarcinoma portion may be a major determinant of patient 
prognosis. In addition, Jung et al. (16) showed that combined 
cancer carries a worse overall prognosis than either HCC or ICC 
alone. Thus, it was considered necessary to treat it according to 
the same strategy used for ICC or a more radical strategy.
LYMPH NODE METASTASES AND THE SIGNIFI-
CANCE OF LYMPH NODES DISSECTION
There have been very few reports of the pattern of lymphatic 
spread of ICC. This pattern was elucidated to help define the 
extent of radical lymph node dissection. Thirty-nine consecu-
tive patients who underwent hepatectomy with radical lymph 
node dissection were reviewed retrospectively (1). Lymph node 
metastases were detected in 24 (62%) of the 39 patients. The 
metastatic nodes were found in the hepatoduodenal ligament, 
along the common hepatic artery, around the abdominal aorta, 
on the posterior surface of the head of the pancreas, along the 
left gastric artery, along the superior mesenteric artery, around 
the celiac artery, along the lesser curvature of the stomach, and 
around the cardia only in the left peripheral and hilar types of 
cholangiocarcinoma, whereas all other sites included both the 
left or right peripheral type and the hilar type cholangiocarci-
noma. ICCs, irrespective of their intrahepatic location, spread 
mainly to the nodes in the hepatoduodenal ligament, and then 
to the para-aortic nodes, retropancreatic nodes, or common 
hepatic artery nodes. In addition to these routes of spread, the 
left peripheral type or hilar type of cholangiocarcinoma tends to 
spread along the left gastric nodes through the lesser curvature. 
From our clinicopathological findings and the anatomical fea-
tures, the efferent lymphatic flow from the liver is complicated 
and extensive (1).
A recent meta-analysis of 13 studies, including 1,337 pa-
tients from 2000 to 2018 by Zho et al. (17) showed that there 
were no significant differences in overall survival, disease-free 
survival, or recurrence between a lymph node dissection group 
and a non-lymphnode dissection group. They also found that 
postoperative morbidity was significantly higher in the lymph 
node dissection group. Therefore, they concluded that routine or 
prophylactic lymph node dissection could not be recommended 
because of the uncertain survival benefit. Furthermore, many 
multivariate analyses showed that the significant independent 
predictor of poor prognosis is not the omission of lymph node 
dissection, but the pathological lymph node metastasis itself. 
However, it is not clear whether there is metastasis without 
dissection. If there are cancer cells in the sentinel lymph node 
(18-21), the lymph nodes in the area of the tumor are dissected. 
If there are no cancer cells in the sentinel node, lymph node dis-
section is not performed. Thus, it is more reasonable to search for 
the sentinel lymph node at the location of the tumor. Therefore, 
in the near future, we plan to inject indigo carmine into the liver 
tissue on the tumor side several times around the circumference 
during the operation to search for metastases to determine the 
need for dissection. If the sentinel nodes do not stain well, the 
lymph nodes of the hepatoduodenal ligament, which is the main 
flow of lymph from the liver, are dissected, and if frozen section 
examination is positive for cancer cells, radical dissection is 
performed, but if it is negative, radical dissection may not be 
considered.
ADJUVANT CHEMOTHERAPY FOR ICC
Despite R0 resection, the 5-year survival rate is low, at only 
30%. Multifocal, node- or margin-positive disease is at a higher 
risk of recurrence after resection. A recent adjuvant therapy 
phase III trial from the Partenariat de Recherche en Oncologie 
Digestive-Actions Concertees dans les Cancers Colo-Rectaux 
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at Digestifs (PRODIGE) group reported no survival advantage 
with adjuvant Gemcitabine and Oxaliplatin therapy (22). 
However, recently, immune therapy using programed cell 
death 1 (PD-1) was reported. Kubo et al. (23) showed that, in 
addition to the main tumor, chronic bile duct injury and pre-
cancerous lesions were observed at various sites of the large bile 
duct. Whole-exome analysis of occupational cholangiocarcinoma 
showed that an average of 44.8 somatic mutations per Mb was 
detected in the genome, approximately 30-fold higher than 
observed in typical cholangiocarcinoma. Moreover, a high num-
ber of programmed death-1-positive T cells were found to have 
infiltrated the tumor, suggesting that PD-L1 may interact with 
the PD-1 expressed on T cells in the tumor microenvironment, 
thereby causing immune escape via the PD-1 / PD-L1 axis (24). 
The Ministry of Health and Welfare of Japan classified this type 
of cholangiocarcinoma “occupational ICC”, and a PD-1 inhibitor 
was approved. The treatment outcome with a PD-1 inhibitor in 
this case will be described later. Molecular profiling studies have 
indicated that about 30% to 40% of intrahepatic cholangiocarci-
noma cases have actionable mutations. These include fibroblast 
growth factor receptor (FGFR) and BRAF genetic aberrations. 
Clinical trials targeting these mutations showed that inhibitors 
provided a promising early signal showing clinical efficacy, and 
patients with HCC expressing high vascular endothelial growth 
factor (VEGF) have a very poor prognosis. High expression of 
VEGF in patients with hepatocellular carcinoma (HCC) is asso-
ciated with a poor prognosis. This seems to have led to the begin-
ning of research with lenvatinib, with lenvatinib mesylate as the 
active ingredient. It is an oral multikinase inhibitor. Lenvatinib 
is a vascular endothelial growth factor. In addition to (VEGF) 
receptors VGFR1-3 and fibroblast growth factor (FGF) receptors 
(FGFR),1-4 tumor markers such as platelet-derived growth fac-
tor receptor (PDGFR) PDGFRα, and KIT, this drug has potent 
and selective inhibitory activity against receptor tyrosine kinas-
es involved in angiogenesis and malignancy (25).
Cancer tumor tissues are composed of a number of different 
types of cells, including cancer cells, vascular endothelial cells, 
and stromal cells. They express VGFR and their ligands VEGF 
and FGF, and they also express VEGF and FGFR induced by 
FGF (especially FGFR1). Both signals cause tumor angiogen-
esis. Since hepatocellular carcinoma is a typical pluripotent 
tumor with a developed tumor vascular network, it is thought 
that suppressing both VEGFR and FGFR signals at the same 
time can suppress tumor angiogenesis very effectively. He-
patocellular carcinoma expresses FGFR1-4, suggesting that 
increased FGFR signaling is associated with malignant trans-
formation of cancer cells and a poor prognosis. Lenvatinib has 
a selective inhibitory activity against receptor tyrosine kinases 
such as VEGFR1-3 and FGFR1-4, and it inhibits tumor angio-
genesis and malignant transformation by inhibition of VEGFR 
and FGFR, thus preventing hepatocellular carcinoma (26). It 
was expected to show a therapeutic effect. The global phase 
III study (Study 304, REFLECT) showed that overall survival 
was noninferior to that of sorafenib, so the drugs approved for 
“unresectable hepatocellular carcinoma” expanded for the first 
time in Japan. Tanaka and Kubo (12) have reported a case of 
relapse of ICC treated with a PD-1 inhibitor. A 39-year-old man 
underwent curative liver resection in October 2012, followed by 
adjuvant chemotherapy with S-1(Tegafur) or gemcitabine until 
postoperative 4 years because of a continuous increase in serum 
CA19-9. At postoperative 4 years 1 month, the serum CA19-9 
concentration increased rapidly to 4,140 U / ml with lymph node 
metastasis around the superior mesenteric artery. Although 
the concentration decreased with gemcitabine and cisplatin 
chemotherapy, it increased again to 8,769 U / ml at postoperative 
4 years 11 months. Positron emission tomography (PET) showed 
enlarged para-aortic lymph nodes. They then started the admin-
istration of a PD-1 inhibitor (nivolumab 3 mg / m2) every 2 weeks. 
After seven cycles of treatment, the serum CA19-9 concentration 
decreased to within the normal limit, and PET demonstrated 
diminished lymph nodes. The patient appeared healthy without 
recurrence 12 months after the complete response. Recently, a 
combination of a PD-1 inhibitor and lenvatinib has been report-
ed to be effective for bone metastasis of ICC (26). A significant 
response to anti-PD-1-based immune therapy plus lenvatinib for 
recurrent intrahepatic cholangiocarcinoma with bone metasta-
sis was previously reported.
To date, only 2 cases were reported in which nivolumab, an 
agent against (PD-1), combined with lenvatinib chemothera-
py led to a complete response (26). The safety and efficacy of 
nivolumab-based immunotherapy combined with lenvatinib for 
ICC were not previously reported. A 40-year-old woman was 
identified as having a lesion of 7.0 cm in diameter in the right 
lobe of the liver. Furthermore, they started the administration 
of a PD-1 inhibitor (nivolumab, 3 mg / m2) every 2 weeks. The 
patient was diagnosed as having intrahepatic cholangiocarcino-
ma. Surgery was performed, intraoperative ultrasound showed 
an 8 x 8 cm 2 mass in segment VIII of the liver, invasion of the 
diaphragm could be seen, and the mass was observed to jostle 
against the right and middle hepatic veins. The patient under-
went resection of liver segment VIII, dissection of regional lymph 
nodes, and resection of lesions on the diaphragm. The patient 
developed recurrent lesions in the 5th month after surgery, and 
the cholangiocarcinoma expanded to the right thoracic vertebra 
(Th7-8) in the 6th month. The patient received nivolumab plus 
lenvatinib, and the lesions in the liver decreased in size and 
disappeared after this treatment. Additionally, the metastases 
in the right thoracic vertebral pedicle were stable after 9 months 
of therapy. Although the details of the operation and postopera-
tive course are not described for the second case, both cases are 
described as having shown a complete response in combination 
with chemotherapy. Recently, based on basic research on immu-
notherapy and molecular drug therapy, a small number of clini-
cal trials has tried to determine whether it may also be effective 
for ICC. If this adjuvant therapy is used widely in patients with 
ICC, prognosis must be improved. This is a great pleasure for 
ICC patients with a poor prognosis and for the physicians who 
treat them.
 
PROPOSED STRATEGY OF SURGICAL TREAT-
MENT FOR ICC PATIENTS
After summarizing the review of ICC, we developed a Pro-
posed Strategy to improve the prognosis of ICC patients, as 
shown in Table 1. We decided to use the level because the tumor 
factors would be better expressed at the level than at the stage. 
Please see Table 1 for detail. 
We expect that further investigations will prove the feasibility 
of our proposed strategy.
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